An Exploratory, Placebo-Controlled Trial of Prophylactic Tetracycline for Gefitinib-or Cetuximab-Induced Skin Rash (or Other Epidermal Growth Factor Receptor (EGFR) Inhibitor-Induced Skin Rash)
tetracycline hydrochloride
+ placebo
Supportive Care Study
Summary
Study start date: December 1, 2004
Actual date on which the first participant was enrolled.OBJECTIVES: * Compare the 1-month incidence and severity of gefitinib-, cetuximab-, or other epidermal growth factor receptor inhibitor-induced skin rash development in patients with cancer treated with tetracycline vs placebo. * Compare the toxicity of these drugs in these patients. * Compare the quality of life of patients treated with these drugs who develop vs those who do not develop a rash. * Determine whether patients who discontinue tetracycline at 1 month develop a rash. OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients are stratified according to prior chemotherapy regimen (first-line therapy vs other), concurrent epidermal growth factor receptor inhibitor therapy (gefitinib vs cetuximab vs other), and concurrent corticosteroid therapy (yes vs no). Patients are randomized to 1 of 2 treatment arms. * Arm I: Patients receive oral tetracycline twice daily. * Arm II: Patients receive oral placebo twice daily. In both arms, treatment continues for 4 weeks in the absence of unacceptable toxicity. Quality of life is assessed at baseline and then weekly for 8 weeks. Patients are followed at weeks 4 and 8. PROJECTED ACCRUAL: A total of 126 patients will be accrued for this study.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.130 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Supportive Care Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Criteria
DISEASE CHARACTERISTICS: * Diagnosis of cancer * Began therapy within the past 7 days or plans to begin therapy within 7 days after study entry with one of the following epidermal growth factor receptor inhibitors: * Gefitinib * Cetuximab * Erlotinib * Monoclonal antibody ABX-EGF * ICR-62 * CI-1033 * EMD-72000 * No rash at study entry PATIENT CHARACTERISTICS: Age * 18 and over Hepatic * Bilirubin ≤ 2 mg/dL Renal * Creatinine ≤ 2 mg/dL Other * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective non-hormonal contraception * Able to take oral medication * No history of skin condition that may flare during study treatment * No prior allergic reaction or severe intolerance to tetracycline or one of its derivatives * No severe nausea or vomiting that would preclude retaining study drug PRIOR CONCURRENT THERAPY: Other * More than 1 week since prior tetracycline * No milk products, antacids, or calcium supplements for 2 hours before until 2 hours after drug administration * No other concurrent tetracycline
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.2 intervention groups are designated in this study
50% chance of being blinded to the placebo group
Treatment Groups
Group I
ExperimentalGroup II
PlaceboStudy Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 69 locations
Rush-Copley Cancer Care Center
Aurora, United StatesOpen Rush-Copley Cancer Care Center in Google MapsJoliet Oncology-Hematology Associates, Limited - West
Joliet, United StatesCarle Cancer Center at Carle Foundation Hospital
Urbana, United StatesCCOP - Carle Cancer Center
Urbana, United States